New York State Common Retirement Fund grew its stake in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 14.0% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 204,482 shares of the biotechnology company's stock after buying an additional 25,164 shares during the period. New York State Common Retirement Fund owned 0.34% of Ascendis Pharma A/S worth $28,151,000 at the end of the most recent reporting period.
Several other large investors have also modified their holdings of the stock. Signaturefd LLC boosted its holdings in shares of Ascendis Pharma A/S by 13.2% in the 3rd quarter. Signaturefd LLC now owns 686 shares of the biotechnology company's stock valued at $102,000 after buying an additional 80 shares in the last quarter. Legato Capital Management LLC boosted its stake in Ascendis Pharma A/S by 7.5% during the 4th quarter. Legato Capital Management LLC now owns 1,921 shares of the biotechnology company's stock worth $264,000 after purchasing an additional 134 shares during the period. Wilmington Savings Fund Society FSB purchased a new position in Ascendis Pharma A/S during the 3rd quarter worth $30,000. GAMMA Investing LLC grew its position in Ascendis Pharma A/S by 58.0% during the 4th quarter. GAMMA Investing LLC now owns 583 shares of the biotechnology company's stock worth $80,000 after purchasing an additional 214 shares during the last quarter. Finally, Thrivent Financial for Lutherans grew its position in Ascendis Pharma A/S by 0.3% during the 3rd quarter. Thrivent Financial for Lutherans now owns 78,473 shares of the biotechnology company's stock worth $11,717,000 after purchasing an additional 228 shares during the last quarter.
Ascendis Pharma A/S Stock Down 1.4 %
Shares of NASDAQ ASND traded down $2.15 during midday trading on Friday, hitting $152.43. The company had a trading volume of 444,151 shares, compared to its average volume of 509,524. Ascendis Pharma A/S has a twelve month low of $111.09 and a twelve month high of $161.00. The business has a 50-day simple moving average of $134.54 and a two-hundred day simple moving average of $133.12. The firm has a market capitalization of $9.25 billion, a price-to-earnings ratio of -21.47 and a beta of 0.64.
Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last announced its quarterly earnings data on Wednesday, February 12th. The biotechnology company reported ($0.68) EPS for the quarter, beating the consensus estimate of ($1.32) by $0.64. On average, equities analysts forecast that Ascendis Pharma A/S will post -4.34 EPS for the current year.
Wall Street Analyst Weigh In
ASND has been the topic of several research reports. StockNews.com raised shares of Ascendis Pharma A/S from a "sell" rating to a "hold" rating in a research report on Wednesday, November 20th. TD Cowen lowered their price objective on shares of Ascendis Pharma A/S from $160.00 to $153.00 and set a "buy" rating on the stock in a research report on Friday, November 15th. Cantor Fitzgerald reissued an "overweight" rating and set a $170.00 price objective on shares of Ascendis Pharma A/S in a research report on Tuesday, February 11th. Stifel Nicolaus raised their price objective on shares of Ascendis Pharma A/S from $200.00 to $207.00 and gave the stock a "buy" rating in a research report on Friday, November 15th. Finally, The Goldman Sachs Group raised their price objective on shares of Ascendis Pharma A/S from $200.00 to $225.00 and gave the stock a "buy" rating in a research report on Thursday, February 13th. Two research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company's stock. According to MarketBeat, Ascendis Pharma A/S currently has a consensus rating of "Moderate Buy" and an average price target of $200.21.
Read Our Latest Research Report on ASND
About Ascendis Pharma A/S
(
Free Report)
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.
Further Reading
Before you consider Ascendis Pharma A/S, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ascendis Pharma A/S wasn't on the list.
While Ascendis Pharma A/S currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
